Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens
Public ClinicalTrials.gov record NCT00419081. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIb, Multicenter, Open-Label, Nonrandomized, Repeat-Dose Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine whether Forodesine Hydrochloride is effective in treating patients with relapsed/refractory precursor T-Lymphoblastic Leukemia/Lymphoma who have failed two or more prior treatment regimens.
Study identification
- NCT ID
- NCT00419081
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 100 participants
Conditions and interventions
Interventions
- Forodesine Hydrochloride Sterile Solution, 5 mg/mL Drug
- Forodesine Hydrochloride Capsules (100 mg) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2006
- Primary completion
- Feb 28, 2007
- Completion
- Feb 28, 2007
- Last update posted
- Jan 22, 2012
2006 – 2007
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| Louisana State University Health Sciences Center | Shreveport | Louisiana | 71103 | — |
| New York Medical College Division of Oncology | Valhalla | New York | 10595 | — |
| Liberty Hematology and Oncology | Columbia | South Carolina | 29203 | — |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Leukemia trials
Other public records listing Leukemia. Sorted by last update posted; newest first. Not a recommendation.
- NCT07227584: ALL Backbone in AYAs Recruiting
- NCT04898790: Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant Recruiting
- NCT06152809: CIML NK Cells With Venetoclax for AML Recruiting
- NCT06053268: Mindfulness Interventions to Improve Health Activation, Coping, and Stress Among Childhood Cancer Survivors Active, not recruiting
- NCT07714044: Rutgers University Study of the Genetics of Blood Cancers Not yet recruiting
- NCT06469307: Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE) Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00419081, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 22, 2012 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00419081 live on ClinicalTrials.gov.